Our findings, albeit preliminary, suggest that CTC characterization according to IDO and PD-L1 may promote our understanding of the mechanisms underlying immunotherapy resistance and may provide valuable prognostic information for NSCLC patients treated with anti-PD1 ICIs. Here, IDO1 is linked to non-small cell lung carcinoma.